Anatomy of Viral Persistence

Michael B. A. Oldstone

Viral Immunobiology Laboratory, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America

Ingredients of a Chronic Viral Infection

The many millions of humans who have life-long virus infections represent a major health issue for the 21st century but also a unique opportunity for investigative virologists. For persistent virus infections to endure, two ingredients are essential. The first is a unique strategy of viral replication; that is, instead of killing its host cell, the pathogen causes little to no damage so it can continue to reside in those cells. The second requirement for persistent virus infection is an immune response that does not react to or remove virus-infected cells. Overall, our knowledge of how viral genes and cellular factors interact to allow persistence to occur is incomplete. Although our libraries contain volumes of facts on this subject, many physiologic functions and interrelationships of viral genes with host genes that establish persistence remain, in large part, unknown. We do know that acutely infected cells express viral peptides, which, when attached to host major histocompatibility complex (MHC) molecules on their surfaces, signal the immune system to kill such cells. However, viruses apply numerous avoidance strategies to persist. One is direct selective pressure to suppress the infected host’s innate and/or adaptive immune system that would otherwise destroy them [reviewed (1,2)] [3]. For example, viruses can alter or interfere with the processing of viral peptides by professional antigen-presenting cells, thereby restricting expression of MHC/peptide complexes on cell surfaces, a requirement for activation and expansion of the T cells that normally remove infected cells. Additionally, viruses can downregulate co-stimulatory and/or MHC molecules also required for T cell signaling and expansion; they can inhibit the differentiation of antigen-presenting conventional dendritic cells (cDCs), and can infect effector T and B cells directly. Similarly, to persist in infected cells, viruses can disrupt the processing or migration of viral peptides or viral peptide/MHC complexes to the cells’ surface, thereby removing the recognition signals for activated killer T cells. Finally, viruses that persist frequently infect neurons, which have defects in TAP, a molecule required for the translocation of viral peptides to endoplasmic reticulum (ER) [4,5]. Perhaps neurons can also actively prevent cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells from degranulating and thereby limit the activity of such virus-removing effector cells. Since neurons are essential to health but rarely regenerate when destroyed, Darwinian selection likely caused them to evolve mechanisms to avoid immunologic assault. Such events would allow infected neurons to escape immune recognition and live, as well as allow viruses to persist in a neuronal safe house.

Immunological Tolerance as a Mechanism to Explain Viral Persistence

Viruses can cause persistent infection early in life directly from mother to child in utero or in newborns whose immune system is immature, and even later in adults after the immune system has matured. Infection in early life was initially attributed to immunologic tolerance, that is, deletion or removal of cell clones that generate an antiviral immune response [6]. The model for this concept was congenital lymphocytic choriomeningitis virus (LCMV) infection of mice, a life-long symptomless viral carrier state induced by in utero or neonatal infection [7]. Like early hepatitis B or C virus (HBV/HCV) infection of today, LCMV infection studied in the past (LCMV-carrier mouse) was characterized by persistent high titers of virus throughout life without detectable antiviral immune response. This pattern was duplicated in vertically transmitted murine retroviral infections. Thus immunologic tolerance was defined (originally in the LCMV-carrier model) as 1) resistance of normal newborn mice to a viral dose lethal for mature adults; 2) presence of high titers of virus in organs and blood of adults infected in utero or neonatally with resistance to an ordinarily lethal LCMV challenge; and 3) absence of complement-fixing or neutralizing antibodies and of LCMV-specific CTLs (later after the discovery of CTLs) in adults infected in utero or neonatally.

Problems with the Immunological Tolerance Model

However, results from our work [8,9] and that of Jamieson and Ahmed [10] indicated major problems with that theory. First, free antiviral antibodies are present not in the circulation but bound to viruses and viral antigens to form v-Ab complexes. These v-Ab complexes deposit primarily in the glomeruli of kidneys, blood vessels, and choroid plexus. Specific anti-LCMV antibodies are readily isolated from the complex by using a low ionic and low pH buffer and quantitatively comprise over 65% of the total immunoglobulin extracted from the glomeruli, a factor 50 to 100 times greater than the specific antiviral LCMV antibody found in the immunoglobulin fraction of adult mice immunized with LCMV [8]. A similar scenario occurs with the in utero or neonatal murine retroviral infections [9]. Further, circulating and glomerular-deposited v-Ab complexes are found in humans with persistent viral infections.

Specific antiviral CTLs are rarely found in adult mice or in humans persistently infected early in life. Reconstitution of virus-specific T cells first shown by adoptive transfer of anti-LCMV-specific CD4 and CD8 T cells readily purged viruses and cleared infection from blood and tissues of LCMV-carrier mice [11]. After virus was cleared, these adult mice, when rechallenged with...
LCMV, generated a robust specific anti-LCMV CTL response with normal kinetics and intensity and developed immunologic memory, that is, protection against an ordinarily lethal intracerebral challenge with LCMV [10].

Therefore, we conclude that viral infection initiated in neonates or in utero does not lead to deletion of T or B cell clones specific for the virus [8–10]. Rather, antibodies are made but do not circulate freely in blood, because they quickly bind to the virus (viral antigen) that is in excess to form immune complexes. Indeed, deposition of such v-Ab complexes leads to tissue injury that accompanies persistent infections. Further, detection of immune complexes is often a reliable marker for persistent virus infection. T cell clones are not deleted, but they are not active or observed until the viral load is lowered or removed. For the treatment of HCV and HBV carriers infected in utero or neonatally, who also fail to show virus-specific T cells, these findings suggest that removal of virus and viral antigens followed by specific immunization may provide a cure.

Viruses Actively Suppress the Host’s Immune Responses

Immune responses reflect the sum of positive versus negative regulators of that response. Negative regulators function to prevent an excessive immunologic response leading to immunopathologic disease. Of those so far identified [12–15], IL-10 [13,14] and PD-L1 [12] have claimed the most interest. They evidently function via separate pathways [13,16], so combination therapy that neutralizes both has been more effective than removal of either one alone [16].

Viruses that initiate persistent infections in juveniles or adults take advantage of this negative regulatory system by actively causing hosts to make regulators that turn off or exhaust the expected antiviral immune response. The discovery that viruses can escape immunologic attack and persist by this means again came from the study of LCMV infection in its natural murine host [12–14] and has been extended to studies of humans persistently infected with HIV and HCV [17–21] and primates infected with simian immunodeficiency virus [22].

In the LCMV persistent infection induced in adults, IL-10 is produced primarily by virus-infected cDCs and perhaps by B cells [13]. In vivo, neither CD4 nor CD8 T cells produce significant amounts of IL-10. Still not clear, though, is which cells IL-10 affects. What is known is that by 9 days after a persistent LCMV infection is initiated in adult mice, T cells become unresponsive; that is, they fail to or poorly lyse virus-infected targets and do not make the positive immune regulators IL-2, interferon-γ, or TNF-α. However, when IL-10 is blocked with antibody to IL-10 receptors, T cell functions are restored, and their numbers increase sufficiently to clear virus from blood and tissues [13]. Interestingly, although IL-10 plays a major role in T cell exhaustion of adult mice persistently infected with LCMV, as yet no similar role for IL-10 has been found in the persistent infection of adults infected in utero or neonatally (D. Brooks, D. McGavern, M. Oldstone, unpublished data).

Figure 1. Cartoon of the initiation of an uncontrolled persistent virus infection or a controlled acute virus infection in immunocompetent adults. Dendritic cells (DC) present viral peptide/MHC complexes to activate T cells. There is an initial expansion phase following infections that lead to either clearance of the virus or virus persistence. For virus clearance, following the acute infection positive immune regulators (IL-2, IFN-γ, TNF, etc.) are generated that expand the effector virus-specific T cell pool, resulting in elimination of virally infected cells, termination of the infection, and resultant development of immune memory. By contrast, with viruses that persist there is a decreased expansion, and in some cases deletion, of virus-specific T cells. Remaining T cells become exhausted or hyporesponsive and are defective in the release of positive immune regulators and hence are unable to terminate the virus infection. The cause is the virus’ induction of negative regulators of the immune response, i.e., IL-10 and PD-L1, and the cure is the blockade of such negative regulators with appropriate antibodies (see [12–14]).

doi:10.1371/journal.ppat.1000523.g001
PD-1 expression increases on T cells during persistent LCMV infection and, as stated above, these T cells become hyporesponsive or exhausted and cannot clear infection [12,15]. Blockade of PD-L1 by specific antibody restores T cell function, which then allows these effector T cells to control the virus infection [12].

The exploration and understanding of negative immune regulators, including IL-10 and PD-1, are still at an early stage; nevertheless, the implications are important and profound. First, exhausted or hyporesponsive T cells found in persistent infections can be resurrected to functional capacity. This is true not only for the LCMV model in which the phenomenon was uncovered [12–14], but also for HIV and HCV in vitro and simian immunodeficiency virus in vivo [17–22]. Second, the environment in which negative regulators are induced by the virus provides one of the major problems in treating persistent infections. Our prediction is that when vaccination strategies to treat persistent infection fail, the likely cause is not a faulty immunogen or adjuvant approach, but overwhelming control of the environment by negative regulators. Indeed, therapeutic vaccination against ongoing persistent LCMV infection was effective only when IL-10 or PD-L1 was first neutralized [23,24].

Clearance of a persistent LCMV infection requires virus-specific CD4 T cell help to assist virus-specific CD8 T cells [25–28]. Recently, IL-21 was identified as essential for CD4 T cell help and allowing CD8 T cells to control the persistent infection [29–31].

**The Future and Potential Applications for Treating Persistent Viral Infections**

Currently our laboratory and others are engaged in the discovery of additional negative immune regulators and their signaling pathway(s) using gene chip and forward genetics technology. These projects have a multitude of applications. Some examples are the development of pharmacologic small molecules as effective antagonists of negative immune regulators, the use of transient negative regulator blockers as an adjuvant approach to enhance both prophylactic and therapeutic vaccination, and the determination of how long during the course of persistent virus infection exhausted T cells can be rescued to become antiviral effector T cells. As always, the goal is to understand basic principles in viral pathogenesis and to extend results in the murine model to resolve persistent infections of humans.

**Acknowledgments**

This is Publication Number 20069 from The Scripps Research Institute. The author acknowledges the work of many past postdoctoral fellows and colleagues who contributed to this work, including Michael Buchmeier, Raymond Welsh, J. Lindsay Whitton, Rafi Ahmed, Yves Riviere, Etienne Joly, Lennart Mucke, Jean-Edouard Gairin, Peter Southern, Maria Salvato, Persephone Borrow, Claire Evans, Juan Carlos de la Torre, Glenn Rall, Noemi Sevilla, Dietmar Berger, Matthias von Herrath, Dirk Homann, Kevin Campbell, David Brooks, Dorian McGavern, and Elina Zuniga.
References

1. Biron C, Sen GC. In: Innate response to viral infections. In: Kneipe D, Howley P, eds. Fields virology. Fifth edition. Philadelphia: Lippincott Williams & Wilkins. pp 249–278.

2. Braciale TJ, Hahn YS, Burton DR. The adoptive immune response to viruses. In: Kneipe D, Howley P, eds. Fields virology. Fifth edition. Philadelphia: Lippincott Williams & Wilkins. pp 279–326.

3. Zumiga EJ, Law LY, Mack L, Mendosa M, Oldstone MBA (2008) Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. Cell Host Microbe 4: 374–386.

4. Joly E, Manke L, Oldstone MBA (1991) Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science 253: 1293–1295.

5. Joly E, Oldstone MBA (1992) Neuronal cells are deficient in loading peptides onto MHC class I molecules. Neuron 8: 1165–1190.

6. Burnet FM (1949) The production of antibodies. Melbourne: MacMillan Co.

7. Nishi T, Watanabe K, Oldstone MBA (1985) Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity. J Exp Med 63: 847–861.

8. Oldstone MBA, Dixon FJ (1967) Lymphocytic choriomeningitis: production of antibody by “tolerant” infected mice. Science 158: 1193–1195.

9. Oldstone MBA, Aoki T, Dixon FJ (1972) The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A 69: 134–138.

10. Jamieson BD, Ahmed R (1988) T-cell tolerance: exposure to virus in utero does not cause a permanent deletion of specific T cells. Proc Natl Acad Sci U S A 85: 2263–2268.

11. Oldstone MBA, Blount P, Southern PJ, Lamperti PW (1986) Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 321: 239–243.

12. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8+ T cells during chronic viral infection. Nature 439: 692–697.

13. Brooks DG, Trifilo MJ, Eden M, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301–1309.

14. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. (2006) Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203: 2461–2472.

15. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29–37.

16. Brooks DG, Ha SJ, Elesasser H, Sharpe AH, Freeman GJ, et al. (2008) IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A 105: 20428–20433.

17. Landay AL, clerici M, Hashemi F, Kessler H, Berzofsky JA, et al. (1996) In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis 173: 1083–1091.

18. Day CL, Kaufmann DE, Kierpela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.

19. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203: 2223–2227.

20. Barrett L, Gallant M, Howley C, Bowmer ML, Hirsch G, et al. (2008) Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. BMC Immunol 1: 28.

21. Brockman MA, Kwon JS, Tigue DP, Pavlik DF, Roseau PC, et al. (2009) IL-10 is upregulated in multiple cell types during viroemic HIV infection and reversibly inhibits virus-specific T cells. Blood. Epub ahead of print doi:10.1182/blood-2008-12-191296.

22. Velay V, Titaun V, Zhu H, Bhuain S, Pladevaya A, et al. (2009) Enhancing HIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206–210.

23. Brooks DG, Lee AM, Elesasser H, McGavern DB, Oldstone MBA (2008) IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 205: 533–541.

24. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, et al. (2008) Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205: 545–555.

25. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, et al. (1994) Enhanced establishment of a virus carrier state in adult CD8+ T-cell-deficient mice. J Virol 68: 4700–4704.

26. Maloufian M, Conception RJ, Ahmed R (1994) CD8+ T cell are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056–8063.

27. Tishon A, Lewicki H, Rall G, von Herrath M, Oldstone MBA (1995) An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 212: 244–250.

28. Berger DF, Homann D, Oldstone MBA (2000) Defining parameters for successful immunocytotherapy of persistent viral infection. Virology 269: 257–263.

29. Elesasser H, Sauer K, Brooks DG (2009) IL-21 is required to control chronic viral infection. Science 324: 1569–1572.

30. Frohlich A, Kielow J, Schmitz I, Freigang S, Shamshiev AT, et al. (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576–1580.

31. Yakis JS, Du M, Zajac AJ (2009) A viral role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572–1576.

32. Sevilla N, Kunz S, Holz A, Lewicki H, Homann D, et al. (2000) Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med 192: 1249–1260.

33. Kunz N, Sevilla N, McGavern DB, Campbell KP, Oldstone MBA (2001) Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol 155: 301–310.

34. Mueller SN, Maloufian M, Clennens DM, Sharpe AH, Freeman GJ, et al. (2007) Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci USA 104: 15430–15435.